Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 15/20 | 0.49 |
| ▸ | PIK3CA | P42336 | 15/20 | 0.45 |
| ▸ | PIK3CB | P42338 | 10/20 | 0.45 |
| ▸ | PIK3CG | P48736 | 10/20 | 0.45 |
| ▸ | MTOR | P42345 | 4/20 | 0.45 |
| ▸ | ATR | Q13535 | 3/20 | 0.45 |
| ▸ | PARP1 | P09874 | 1/20 | 0.45 |
| ▸ | PRKDC | P78527 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12267856 | 0.88 | PIK3CD (0.52) | PIK3CDPIK3CAPIK3CBPIK3CGMTOR | |
| SCHEMBL13349747 | 0.88 | PIK3CD (0.51) | PIK3CDPIK3CAPIK3CBPIK3CGMTOR | |
| SCHEMBL2397265 | 0.86 | PIK3CD (0.54) | PIK3CDPIK3CAPIK3CBPIK3CGMTOR | |
| SCHEMBL2395806 | 0.86 | PIK3CD (0.66) | PIK3CDPIK3CAPIK3CBPIK3CGMTOR | |
| SCHEMBL2394249 | 0.84 | PIK3CD (0.46) | PIK3CDPIK3CAPIK3CBPIK3CGMTOR | |
| SCHEMBL12267760 | 0.84 | PIK3CD (0.57) | PIK3CDPIK3CAPIK3CBPIK3CGMTOR | |
| SCHEMBL2394642 | 0.83 | PIK3CD (0.52) | PIK3CDPIK3CAPIK3CBPIK3CGMTOR | |
| SCHEMBL2394845 | 0.83 | PIK3CD (0.46) | PIK3CDPIK3CAPIK3CBPIK3CGMTOR | |
| SCHEMBL2394645 | 0.83 | PIK3CD (0.52) | PIK3CDPIK3CAPIK3CBPIK3CGMTOR | |
| SCHEMBL2396396 | 0.83 | PIK3CD (0.47) | PIK3CDPIK3CAPIK3CBPIK3CGMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2215090-A1 | PURINE DERIVATIVES USEFUL AS PI3 KINASE INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2010-08-11 | — | — | EP | claimed |
| WO-2009053716-A1 | PURINE DERIVATIVES USEFUL AS PI3 KINASE INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2009-04-30 | — | — | WO | claimed |
| EP-2215090-B1 | PURINE DERIVATIVES USEFUL AS PI3 KINASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2015-03-04 | — | — | EP | disclosed |
| US-20110230464-A1 | PURINE DERIVATIVES USEFUL AS P13 KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-09-22 | — | — | US | disclosed |
| US-20110230464-A1 | PURINE DERIVATIVES USEFUL AS P13 KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-09-22 | — | — | US | disclosed |
| US-20110230464-A1 | PURINE DERIVATIVES USEFUL AS P13 KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-09-22 | — | — | US | disclosed |
| EP-2365810-A2 | PHOSPHATIDYLINOSITOL-3-KINASE P110 DELTA-TARGETED DRUGS IN THE TREATMENT OF CNS DISORDERS | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services (US) | 2011-09-21 | — | — | EP | disclosed |
| EP-2225235-A2 | THIAZOLE CARBOXAMIDE DERIVATIVES AND THEIR USE TO TREAT CANCER | Schering Corporation (US) | 2010-09-08 | — | — | EP | disclosed |
| EP-2215090-A1 | PURINE DERIVATIVES USEFUL AS PI3 KINASE INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2010-08-11 | — | — | EP | disclosed |
| WO-2010065923-A2 | PHOSPHATIDYLINOSITOL-3-KINASE P110 DELTA-TARGETED DRUGS IN THE TREATMENT OF CNS DISORDERS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2010-06-10 | — | — | WO | disclosed |
| WO-2009058729-A2 | THIAZOLE CARBOXAMIDE DERIVATIVES AND THEIR TO TREAT CANCER | SCHERING CORPORATION (US) | 2009-05-07 | — | — | WO | disclosed |
| WO-2009053716-A1 | PURINE DERIVATIVES USEFUL AS PI3 KINASE INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2009-04-30 | — | — | WO | disclosed |
| WO-2009053716-A1 | PURINE DERIVATIVES USEFUL AS PI3 KINASE INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2009-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230464-A1 | PURINE DERIVATIVES USEFUL AS P13 KINASE INHIBITORS | PIK3CA, PIK3CD, PI4KA | PIK3CD 2/4885PIK3CA 1/4885PIK3CB 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.